Subsequent multifactor analysis showed that EGFR was indeed an independent risk factor for brain metastasis in NSCLC patients (P = .012), a finding consistent with the results of studies by Eichler et al10 and Liu et al.17 It may be attributed to the fact that EGFR mutations are involved in the occurrence of brain metastasis from lung cancer, or it may be due to the use of EGFR‐TKI that leads to a longer survival in patients with an EGFR mutation. Here, EGFR is linked to non-small cell lung carcinoma.